USA – The U.S. government will buy Tpoxx intravenous formulation from SIGA Technologies Inc.’s IV for US$26 million.

New York City-based pharmaceutical company, SIGA said it plans to will deliver the medication in 2023.

The business claimed that the IV formulation is an “essential option” for patients who are unable to swallow pills, especially because monkeypox can result in mouth blisters and rashes.

In a statement, Phil Gomez, Ph.D., the CEO of SIGA, said that the contract and the funding of a study of IV TPOXX show the growing necessity of a broad-based response to the enormous threats posed by the orthopox family of viruses which include smallpox and monkeypox.

Monkeypox is a disease of worldwide public health significance given that it affects the rest of the world as well as countries in west and central Africa.

 

SIGA has also received multiple orders for the oral drug from Canada, as well as countries in Europe and the Asia-Pacific region.

Newer vaccines, diagnostics, and antiviral medicines are being developed to ensure worldwide preparation in the event of the return of smallpox that could now help prevent and treat monkeypox.

According to the most recent Centers for Disease Control and Prevention (CDC), about 32,000 instances of monkeypox have been reported in more than 80 countries where the disease is uncommon.

With approximately 9,500 instances, the United States leads the globe in cases of monkeypox; Spain, Germany, and the United Kingdom are next with more than 5,000 cases each.

Except for France and Brazil, which have both reported more than 2,000 instances, the remaining nations have only recorded less than 1,000 cases.

In the US, New York tops the U.S. with more than 2,000 cases. Florida has recorded the most cases (1,766), followed by California (1,300), Florida (976), Georgia, Texas, and Illinois (more than 700), and California (1,300).

Only Wyoming has so far recorded no instances, while the other states have reported fewer than 300 cases.

The US Centers for Disease Control and Prevention (CDC) has provided guidance for use under “expanded access” as an experimental drug.

The government has also chosen to fund post-marketing field research for the drug’s intravenous form, according to the SIGA.

SIGA has also received multiple orders for the oral drug from Canada, as well as countries in Europe and the Asia-Pacific region.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE